FDA Approval: KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) — Type 1 - New Molecular Entity
Policy FDA-BLA761467 · Oncology
KEYTRUDA QLEX, an injectable drug approved under BLA761467, will be billed under Part B. Billing teams should verify the specific J-code upon FDA label publication.